Tag: pharmaceuticals
-
Engineered T-Cells Shown Reducing Non-Hodgkin Lymphoma
A clinical trial testing synthetic immune system cells shows after 6 months the cells can generate a full or partial response in many patients with non-Hodgkin lymphoma.
-
Trial Begins Testing Enhanced Cord Blood Stem Cells
A clinical trial testing transplant grafts derived from umbilical cord blood as an alternative to bone marrow stem cells for people with blood-related cancers is treating its first patient.
-
Public Access to Drugs Meets Health Needs, Cuts Costs
A study shows adding universal access to essential drugs as part of Canada’s health care system would meet much of that country’s pharmaceutical needs and save billions of dollars.
-
Duchenne Gene-Editing Company Launched, Raising $5M
A biotechnology start-up is applying a process for editing-out disease-causing mutations to correct the inherited disorder Duchenne muscular dystrophy.
-
Genome Editing Builds Viral Disease Resistance in Pigs
Veterinary researchers used Crispr-Cas9, an emerging genome editing technique, to produce pigs with cells resistant to a common viral disease affecting commercial herds.
-
Nuclear Cancer Therapy Company Launches, Raises $25M
A new company developing cancer therapies combining nuclear radiation and synthetic antibodies is starting up in Hamilton, Ontario.
-
Patent Issued for Peptides in Diabetes Gene Therapy
A U.S. patent was issued today for synthetic peptides that support gene therapies developed to treat type 2 diabetes and heart failure.
-
Stem Cells Launched on Current SpaceX Flight
Yesterday’s SpaceX launch from NASA’s Kennedy Spaceflight Center includes a shipment of adult stem cells to test their growth and proliferation in weightless conditions.
-
Online Pharmacies Seen Fueling Antibiotic Overuse
A study of pharmacies selling drugs online shows many of these sites offer antibiotics to consumers in the U.K. without prescriptions, which would be illegal in retail drug stores.
-
Patent Office Decides for Broad and Editas in Crispr Case
The U.S. Patent and Trademark Office decided that the gene editing processes developed by Broad Institute and licensed to Editas Medicine do not interfere with techniques for genome editing created by University of California at Berkeley.